ArticleBMJ open gastroenterology2025
Impact of antithrombotic therapy on colonoscopy outcomes in FIT-positive patients: implications for polyp detection, diverticulosis and normal findings.
Article in BMJ open gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveFaecal immunochemical test (FIT) is widely used in colorectal cancer (CRC) screening, but the impact of antithrombotic therapy on colonoscopy outcomes remains unclear. This study aimed to compare polyp detection rate (PDR) and prevalence of non-neoplastic findings in FIT-positive patients undergoing colonoscopy, stratified by antithrombotic therapy.
methodsWe conducted a retrospective, multicentre cohort study of 26 280 FIT-positive colonoscopies performed between 2016 and 2023 across seven gastroenterology centres in Israel. The FIT positivity threshold was 75 ng/mL. Patients were grouped by therapy: antiplatelets (n=1904), anticoagulants (n=262) or no antithrombotic treatment (n=24 079). Using crude and matched analyses, we assessed PDR, adenoma detection rate (ADR), CRC detection and diverticulosis prevalence.
resultsPatients on antithrombotics were older (mean 65.9±7 vs 61.0±8 years; p<0.001), more often men (65.2% vs 50.1%; p<0.001) and had higher comorbidity rates. Crude PDR was higher in antithrombotic users (55.5% vs 51.9%; p=0.001), but ADR was similar (28.2% vs 28.3%; p=0.950). Diverticulosis was more prevalent in the antithrombotic group (24.0% vs 17.4%; p<0.001). After matching for age and sex (n=2201 pairs), all previously significant associations were eliminated: PDR were no longer different (55.5% vs 53.1%; p=0.112), diverticulosis prevalence became identical (24.0% vs 24.3%; p=0.799) and normal colonoscopy rates were similar (27.5% vs 29.6%; p=0.123). ADRs remained comparable (28.2% vs 26.7%; p=0.269), and CRC detection rates were identical (2.0% vs 2.0%; p=0.998).
conclusionDemographic confounding, rather than antithrombotic therapy per se, explains the crude associations in colonoscopy outcomes. The matched analysis demonstrates that antithrombotics do not independently affect polyp detection, diverticulosis prevalence or adenoma detection when age and sex are controlled for. These findings support the continued use of antithrombotics during CRC screening, shifting clinical interpretation from medication-based to demographic-based risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.